THERAPY OF TP53 MUT MDS

被引：0
|
作者：
Sallman, D. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS24
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)
    Koji Ando
    Yoshiaki Nakamura
    Hiroyuki Kitao
    Mototsugu Shimokawa
    Daisuke Kotani
    Hideaki Bando
    Tomohiro Nishina
    Takanobu Yamada
    Satoshi Yuki
    Yukiya Narita
    Hiroki Hara
    Takashi Ohta
    Taito Esaki
    Yasuo Hamamoto
    Ken Kato
    Yoshiyuki Yamamoto
    Keiko Minashi
    Koushiro Ohtsubo
    Naoki Izawa
    Hisato Kawakami
    Takeshi Kato
    Taroh Satoh
    Naohiro Okano
    Akihito Tsuji
    Kentaro Yamazaki
    Takayuki Yoshino
    Yoshihiko Maehara
    Eiji Oki
    British Journal of Cancer, 2023, 129 : 1032 - 1039
  • [22] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    MODERN PATHOLOGY, 2018, 31 : 524 - 525
  • [23] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    LABORATORY INVESTIGATION, 2018, 98 : 524 - 525
  • [24] Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)
    Ando, Koji
    Nakamura, Yoshiaki
    Kitao, Hiroyuki
    Shimokawa, Mototsugu
    Kotani, Daisuke
    Bando, Hideaki
    Nishina, Tomohiro
    Yamada, Takanobu
    Yuki, Satoshi
    Narita, Yukiya
    Hara, Hiroki
    Ohta, Takashi
    Esaki, Taito
    Hamamoto, Yasuo
    Kato, Ken
    Yamamoto, Yoshiyuki
    Minashi, Keiko
    Ohtsubo, Koushiro
    Izawa, Naoki
    Kawakami, Hisato
    Kato, Takeshi
    Satoh, Taroh
    Okano, Naohiro
    Tsuji, Akihito
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Maehara, Yoshihiko
    Oki, Eiji
    BRITISH JOURNAL OF CANCER, 2023, 129 (06) : 1032 - 1039
  • [25] TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy
    Hu, Wanglai
    Chen, Song
    Thorne, Rick F.
    Wu, Mian
    AUTOPHAGY: BIOLOGY AND DISEASES: BASIC SCIENCE, 2019, 1206 : 127 - 149
  • [26] Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS
    Reilly, Sean Patrick
    Bi, Xia
    French, Zachary
    Wilde, Lindsay
    Palmisiano, Neil
    BLOOD, 2022, 140 : 12339 - 12340
  • [27] Response to azacitidine is independent of TP53 mutations in higher-risk MDS
    Mueller-Thomas, C.
    Rudelius, M.
    Wolf, P.
    Schmidt, B.
    Platzbecker, U.
    Germing, U.
    Peschel, C.
    Gotze, K.
    ONKOLOGIE, 2012, 35 : 31 - 31
  • [28] MDS and TP53: When One Hit Just Isn't Enough . . .
    Kent, David G.
    HEMASPHERE, 2020, 4 (06):
  • [29] Genetic instability and TP53 alterations in MDS and sAML with complex aberrant karyotype
    Schaab, R.
    Ganster, C.
    Shirneshan, K.
    Dierks, S.
    Martin, R.
    Sole, F.
    Germing, U.
    Palomo, L.
    Mies, A.
    Braulke, F.
    Hildebrandt, B.
    Kaivers, J.
    Platzbecker, U.
    Kroeger, N.
    Doehner, K.
    Glass, B.
    Nickelsen, M.
    Schanz, J.
    Bacher, U.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 133 - 133
  • [30] IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC TRASPLANT
    Diez Campelo, M.
    Caballero, J. C.
    del Rey, M.
    Janusz, K.
    Lumbreras, E.
    Abaigar, M.
    Robledo, C.
    Jerez, A.
    Valcarcel, D.
    Calderon-Cabrera, C.
    Hernandez-Rivas, J. M.
    del Canizo, M. C.
    HAEMATOLOGICA, 2014, 99 : 348 - 348
12345